Insight Molecular Diagnostics (IMDX) Asset Writedowns and Impairment (2020 - 2024)
Insight Molecular Diagnostics' (IMDX) quarterly Asset Writedowns and Impairment came in at $36.9 million in Q4 2024, up 922600.0% year-on-year from N/an in Q1 2024, and up 922600.0% quarter-over-quarter from -$4000.0 in Q4 2023.
Insight Molecular Diagnostics (IMDX) Asset Writedowns and Impairment (2020 - 2024) Analysis & Trends
Insight Molecular Diagnostics has disclosed Asset Writedowns and Impairment across 3 years of filings, most recently posting $36.9 million for Q4 2024.
- Asset Writedowns and Impairment for Q4 2024 came in at $36.9 million, up 922600.0% year-over-year; the trailing twelve-month figure through Dec 2024 was $38.7 million (up 472.1% YoY), and the FY2025 annual result was $14.6 million, down 65.16% from the prior year.
- Asset Writedowns and Impairment came in at $36.9 million for Q4 2024 at Insight Molecular Diagnostics, up from -$4000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $36.9 million in Q4 2024 to a low of -$334000.0 in Q3 2020.
- The 3-year median for Asset Writedowns and Impairment is $333500.0 (2020), against an average of $5.5 million.
- Peak annual rise in Asset Writedowns and Impairment reached 922600.0% in 2024, while the deepest fall reached 922600.0% in 2024.
- Insight Molecular Diagnostics' Asset Writedowns and Impairment stood at $334000.0 in 2020, then sank by 101.2% to -$4000.0 in 2023, then jumped by 922600.0% to $36.9 million in 2024.
- The last three Asset Writedowns and Impairment figures came in at $36.9 million (Q4 2024), -$4000.0 (Q4 2023), and $1.8 million (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Waters | 30,529.42 Bn | 30,528.96 Bn | 1.11 Bn |
| 2 | Thermo Fisher Scientific | 183.75 Bn | 180.50 Bn | 7.74 Bn |
| 3 | Danaher | 133.13 Bn | 127.43 Bn | 3.59 Bn |
| 4 | Idexx Laboratories | 46.14 Bn | 45.94 Bn | 722.74 Mn |
| 5 | Agilent Technologies | 38.20 Bn | 36.39 Bn | 990.00 Mn |
| 6 | Natera | 31.50 Bn | 30.40 Bn | 696.04 Mn |
| 7 | Iqvia Holdings | 31.34 Bn | 29.36 Bn | 1.36 Bn |
| 8 | Illumina | 24.51 Bn | 23.36 Bn | 721.00 Mn |
| 9 | Mettler Toledo International | 23.53 Bn | 23.47 Bn | 555.82 Mn |
| 10 | Insight Molecular Diagnostics | 4.52 Mn | -24.41 Mn | 15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 36.90 Mn |
| Dec 31, 2024 | 36.90 Mn |
| Dec 31, 2023 | -4,000.00 |
| Dec 31, 2023 | -4,000.00 |
| Sep 30, 2023 | 1.81 Mn |
| Sep 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | -50,000.00 |
| Jun 30, 2023 | -50,000.00 |
| Mar 31, 2023 | 5.00 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2020 | 334,000.00 |
| Dec 31, 2020 | 334,000.00 |
| Sep 30, 2020 | -334,000.00 |
| Sep 30, 2020 | -334,000.00 |
| Jun 30, 2020 | 333,000.00 |
| Jun 30, 2020 | 333,000.00 |